Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer

2022; Nature Portfolio; Volume: 4; Issue: 2 Linguagem: Inglês

10.1038/s43018-022-00489-5

ISSN

2662-1347

Autores

Tizita Zeleke, Qingfei Pan, Codruța Chiuzan, Maika Onishi, Yuxin Li, Haiyan Tan, Mariano J. Alvarez, Erin Honan, Min Yang, Pei Ling Chia, Partha Mukhopadhyay, Sean Kelly, Ruby Wu, Kathleen Fenn, Meghna S. Trivedi, Melissa Accordino, Katherine D. Crew, Dawn L. Hershman, Matthew Maurer, Simon Jones, Anthony A. High, Junmin Peng, Andrea Califano, Kevin Kalinsky, Jiyang Yu, Jose Silva,

Tópico(s)

Protein Degradation and Inhibitors

Referência(s)